Causes of newborn salt loss beyond 21‑hydroxylase deficiency
Official title: Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT07473804 · Data updated 2026-11-12
This project sees how often rare endocrine conditions besides 21‑hydroxylase deficiency cause dangerous salt loss in newborns and describes their clinical, genetic, and treatment features.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Year to 35 Years |
| Sex | All |
| Enrollment | 25 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Status | Recruiting |
| Started | April 14, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | March 16, 2026 |
| Trial ID | NCT07473804 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Newborns who developed salt loss with serum sodium <130 mEq/L between 0 and 60 days of age, were managed at the Bologna center between January 1, 1989 and December 31, 2023, do not have 21‑hydroxylase deficiency, and whose guardians provided consent.
✕Probably not a fit
Infants whose salt loss is clearly due to infection or other non‑endocrine causes, those already diagnosed with 21‑hydroxylase deficiency, or those born/treated outside the specified center and dates are unlikely to benefit from inclusion.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational, retrospective cohort reviews neonatal salt‑loss cases managed at IRCCS Azienda Ospedaliero‑Universitaria di Bologna from 1989 to 2023. Eligible infants had onset of salt loss between birth and 60 days with documented serum sodium <130 mEq/L and were confirmed not to have 21‑hydroxylase deficiency. Investigators extract clinical presentation, laboratory data, genetic test results, treatments (salt replacement, mineralocorticoid and/or glucocorticoid therapy) and outcomes to define incidence and the spectrum of congenital endocrine causes. The analysis aims to improve recognition, describe genotype–phenotype correlations, and summarize management approaches for these rare conditions.
Why it matters
Potential benefit: If successful, this work could help clinicians diagnose non‑21OH causes of neonatal salt loss more quickly and choose the right treatments to reduce complications.
How similar studies have gone: Prior retrospective series, including an Italian cohort from 2006–2015, have reported proportions and features of endocrine neonatal salt loss but many rare disorders remain incompletely described.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a diagnosis of endocrine-related salt loss, defined by laboratory findings of hyponatremia (serum sodium \<130 mEq/L) * Age at onset of salt loss between 0 and 60 days of life * Patients born between January 1, 1989 and December 31, 2023 and managed at the Experimental Center * Obtained Informed consent Exclusion Criteria: • Diagnosis of 21OH ISC
Where it's running
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy Recruiting
Study contacts
- Study coordinator: Federico Baronio
- Email: federico.baronio@aosp.bo.it
- Phone: 00390512144816
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fertility and sexual function in people with congenital adrenal hyperplasia
This study will test whether new CAH treatments improve fertility and sexual health in adults with congenital adrenal hyperplasia.
-
Understanding the effects of excess androgen in patients
This study is trying to understand how too much androgen affects people with certain genetic conditions, like congenital adrenal hyperplasia and familial male-limited precocious puberty, by looking at their growth, hormone levels, and overall health.
-
Adrenal Diseases in Modena: A Patient Registry at Modena University Hospital
This study collects medical histories and treatment data from patients with adrenal diseases to see how they are diagnosed and managed in Modena.
-
Crinecerfont safety testing in babies with classic CAH under 4 years old
This study tests whether crinecerfont is safe and tolerable in children under 4 years with classic CAH who have been on hydrocortisone.
-
Atumelnant for children with classic congenital adrenal hyperplasia (Balance-CAH)
This study will test whether atumelnant is safe and helps control hormone levels in children aged 1 to under 18 with classic congenital adrenal hyperplasia.
-
Atumelnant for adults with classic congenital adrenal hyperplasia
This will test whether taking once-daily atumelnant helps adults with classic 21‑hydroxylase deficiency CAH who are already on stable glucocorticoid therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.